TransMedics Group, Inc. (TMDX) Return on equity 2019–2025
TransMedics Group, Inc. (TMDX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
40.2%FY2025 · since FY2019: -61.4% → 40.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 40.2% | +24.7 pp |
| FY2024 | 15.5% | +33.8 pp |
| FY2023 | -18.2% | +1.1 pp |
| FY2022 | -19.3% | +45.8 pp |
| FY2021 | -65.2% | -37.5 pp |
| FY2020 | -27.7% | +33.7 pp |
| FY2019 | -61.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More TMDX financial trends
TMDX RevenueTMDX Net incomeTMDX Net marginTMDX Gross profitTMDX Gross marginTMDX Operating incomeTMDX Operating marginTMDX Operating cash flowTMDX Free cash flowTMDX Capital expendituresTMDX Stock buybacksTMDX Dividends paidTMDX Total assetsTMDX Total liabilitiesTMDX Shareholders’ equityTMDX overview →